Zydus Lifesciences, Venus Pipes & Tubes and IndiGo to see some action today

09 May 2025 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Glatiramer Acetate Injection, 20 mg/mL and 40 mg/mL, single-dose prefilled syringes. Zydus’ generic Glatiramer Acetate Injection is an FDA-approved, AP-rated substitutable generics of Copaxone 20 mg/ml, 40 mg/ml and indicated for the treatment of relapsing forms of Multiple Sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. 

Venus Pipes & Tubes has received LOI from one of India’s leading integrated power plant equipment manufacturers for Stainless Steel Seamless Boiler Tubes used in series of Supercritical and Subcritical Thermal Power Projects worth around Rs 190 crore (excluding GST). Formal order will be released shortly and is expected to be executed progressively during next 12-15 months. 

InterGlobe Aviation (IndiGo) has inked an agreement with Norwegian low-cost carrier Norse Atlantic Airways for damp leasing two more Boeing Dreamliner 787- aircraft bolstering its wide-body fleet. Norse Atlantic in November last year had announced signing a Letter of Intent for six such planes with a reputable airline. IndiGo is expanding its international footprint with plans to launch direct flights to Europe amid the rising international traffic from India. 

REC is planning to increase its exposure to renewable energy projects by about Rs 2.5 lakh crore in next six years to aid India's target of having 500 GW of non-fossil fuel energy by 2030. REC currently has an exposure of about Rs 53,000 crore in renewable energy projects with a total loan book of Rs 5.67 lakh crore as on March 31, 2025. 

IRB Infrastructure has posted a 10 per cent rise in its toll revenue to Rs 554 crore in April compared to Rs 503 crore in the same month last year. Of its 17 tolls, IRB MP Expressway in Maharashtra contributed the major share of Rs 150.7 crore to the total revenue collection in April, up from Rs 140.7 crore contribution in April 2024.

Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Raltegravir Tablets USP, 600 mg. Raltegravir Tablets are bioequivalent to Isentress HD Tablets, 600 mg of Merck Sharp & Dohme LLC. Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin’s Nagpur facility in India.

Ampvolts has signed a Memorandum of Understanding (MoU) with Mecpower Solutions, part of Onix Group of companies, a prominent Solar Power provider. This strategic collaboration aims to advance green mobility solutions by leveraging the synergies of both organizations to develop sustainable & robust EV charging infrastructure in India.

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×